Rare Cancer in our Youth
$ 20.00
Garvan researchers have discovered a potential treatment for osteosarcoma – a rare but aggressive form of youth cancer – in an existing psoriasis drug.
 
Researchers demonstrated that the immune molecule IL23 is central to the development of osteosarcoma, which is often dismissed as a growing pain or injury. By targeting IL23 with psoriasis therapy, researchers successfully shrank osteosarcoma tumours in mice.
 
We hope this new discovery will lead to clinical trials, and better outcomes for young cancer patients. Your donation can help to make clinical trials like these possible for patients with rare cancer.
 
Thank you for your $20 donation

Or Donate Amount of Your Choice